MD3361F1 - Method of treating the infantile cerebral paralysis - Google Patents
Method of treating the infantile cerebral paralysisInfo
- Publication number
- MD3361F1 MD3361F1 MDA20060253A MD20060253A MD3361F1 MD 3361 F1 MD3361 F1 MD 3361F1 MD A20060253 A MDA20060253 A MD A20060253A MD 20060253 A MD20060253 A MD 20060253A MD 3361 F1 MD3361 F1 MD 3361F1
- Authority
- MD
- Moldova
- Prior art keywords
- region
- compositum
- biologically active
- active points
- weeks
- Prior art date
Links
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Inventia se refera la medicina, in special la neurologie, pediatrie, reflexoterapie, si poate fi utilizata pentru ameliorarea calitatii tratamentului bolnavilor cu forme spastice si spastico-hiperchinetice ale paraliziei cerebrale la copii. Metoda,conform inventiei, consta in aceea ca in decurs de 1…2 luni se administreaza preparatele Lymphomyosot, Berberis-Homaccord, Nux vomica-Homaccord cate4…7 picaturi de 3 ori pe zi per os, Coenzyme Compositum cate 0,9…1,8 ml de 2 ori pe saptamana intramuscular, Ubichinon Compositum cate 0,9…1,8 ml de 2 ori pe saptamana intramuscular, Nevroheeli cate 1 pastila de 3 ori pe zi, Spascupreel cate 1 supozitor pe noapte. Incepand cu a treia saptamana de tratament, se administreaza Cerebrum Compositum,Placenta Compositum, Arteria Heel cate 1,0…2,5 mlde 2 ori pe saptamana subcutanat in regiunea punctelor biologic active G14, P7, MC6, TR6, TR5, E36,VB34, RP6, E36, IG3, V62, C5, VB39, VB20, V23, totodata fiecare preparat medicamentos se administreaza in regiunea a 5 puncte biologic active, repetand alternarea lor timp de 3 saptamani. Apoi, in urmatoarele 3 saptamani, aceste preparate in aceeasiconsecutivitate se administreaza in regiunea punctelor biologic active C3, V62, IG3, T14, V10, 13, VB20, 21, T3, 5, V23, 28, 31, 34, iar in urmatoarele 3…4 saptamani in regiunea punctelor biologic active IG12, 15, G14-15, TR3-10, G14, 5, 6, 10, 11,MC5, 8, IG11, P10, VB20, 21, 30, 31, 34, V11, 15, 57, 60, E32, 41, IG3, 9, 14, T4, 14, 20, P5, 7, MC5, 6, GI10.The invention relates to medicine, in particular to neurology, pediatrics, reflexology, and may be used to improve the quality of treatment of patients with spastic and hyper-kinetic spastic forms of cerebral palsy in children. The method, according to the invention, consists in the fact that within 1… 2 months the preparations of Lymphomyosot, Berberis-Homaccord, Nux vomica-Homaccord are administered4… 7 drops 3 times daily per bone, Coenzyme Compositum each 0.9… 1, 8 ml 2 times per week intramuscularly, Ubichinon Compositum each 0.9 ... 1.8 ml 2 times per week intramuscularly, Nevroheels each 1 pill 3 times daily, Spascupreel each 1 suppository per night. Starting with the third week of treatment, Cerebrum Compositum, Placenta Compositum, Heel Artery are administered 1.0 ... 2.5 billion 2 times per week subcutaneously in the region of biologically active points G14, P7, MC6, TR6, TR5, E36, VB34 , RP6, E36, IG3, V62, C5, VB39, VB20, V23, at the same time each drug preparation is administered in the region of 5 biologically active points, repeating their alternation for 3 weeks. Then, in the next 3 weeks, these preparations in the same sequence are administered in the region of biologically active points C3, V62, IG3, T14, V10, 13, VB20, 21, T3, 5, V23, 28, 31, 34, and in the next 3 … 4 weeks in the region of biologically active points IG12, 15, G14-15, TR3-10, G14, 5, 6, 10, 11, MC5, 8, IG11, P10, VB20, 21, 30, 31, 34, V11, 15, 57, 60, E32, 41, IG3, 9, 14, T4, 14, 20, P5, 7, MC5, 6, GI10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20060253A MD3361G2 (en) | 2006-10-27 | 2006-10-27 | Method of treating the infantile cerebral paralysis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MDA20060253A MD3361G2 (en) | 2006-10-27 | 2006-10-27 | Method of treating the infantile cerebral paralysis |
Publications (2)
Publication Number | Publication Date |
---|---|
MD3361F1 true MD3361F1 (en) | 2007-07-31 |
MD3361G2 MD3361G2 (en) | 2008-02-29 |
Family
ID=38331522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20060253A MD3361G2 (en) | 2006-10-27 | 2006-10-27 | Method of treating the infantile cerebral paralysis |
Country Status (1)
Country | Link |
---|---|
MD (1) | MD3361G2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2485983C2 (en) * | 2011-09-16 | 2013-06-27 | Максимильян Григорьевич Кравчик | Method for recovering sensor-motor function of central nervous system and peripheral nerves |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2168976C2 (en) * | 1999-03-01 | 2001-06-20 | Новокузнецкий государственный институт усовершенствования врачей | Method of treating babies with cerebral paralysis |
-
2006
- 2006-10-27 MD MDA20060253A patent/MD3361G2/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2485983C2 (en) * | 2011-09-16 | 2013-06-27 | Максимильян Григорьевич Кравчик | Method for recovering sensor-motor function of central nervous system and peripheral nerves |
Also Published As
Publication number | Publication date |
---|---|
MD3361G2 (en) | 2008-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vinayak et al. | Adverse affects of drugs on saliva and salivary glands | |
Al-Aizari et al. | Oral manifestations of Parry-Romberg syndrome: a review of literature | |
Karasek et al. | The future of melatonin as a therapeutic agent | |
NZ767378A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
MD3361F1 (en) | Method of treating the infantile cerebral paralysis | |
MD3359F1 (en) | Method of conservative treatment of diskal hernia | |
Bech et al. | Dapsone for the treatment of chronic IgA vasculitis (Henoch-Schonlein) | |
ATE366581T1 (en) | APOPTOTIC BODY FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND OTHER NERVOUS DISEASES | |
MD3803F1 (en) | Method of treating hyperkinesia of children | |
MD3906G2 (en) | Method for treating the neurotic enuresis to children | |
MX2023008804A (en) | Liquid formulation of protein and methods of preparing the same. | |
CN100402039C (en) | Hair growth promoting liquid | |
CN105232577A (en) | Technology for growing hair by using adipose-derived stem cell factors | |
MD3927F1 (en) | Method for treating the facial paralysis | |
JP2004189676A (en) | External preparation for ameliorating damaged skin | |
Solomennyi | STUDY OF THE QUALITY COMPOSITION OF MODERN WOUND-HEALING AGENTS BASED ON DECAMETOXIN AND METHYLURACIL | |
Achard | Is the WHO weight for age chart appropriate for infants of the developing world? | |
Rahill | Mammary gland changes during chlorpromazine therapy | |
MD3885F1 (en) | Method for polyparasitosis complex treatment to cattle | |
CN101919889A (en) | External angelica pus-eliminating ointment | |
ATE160091T1 (en) | BOXWOOD PREPARATION FOR TREATMENT OF HIV INFECTION | |
Aparna et al. | An effective management of collapse compression fracture through Panchakarma-A Case Study | |
KR20240086411A (en) | Medium composition for inhibiting cytotoxicity induced by degenerative neuropathogenic factors | |
Moratschek et al. | Treatment Considerations During Lactation for Adolescents with Bipolar Disorder | |
Boots et al. | DEGENERATIVE JOINT DISEASE OF THE HIP: RELIEF OF SYMPTOMS FOLLOWING CORTISONE THERAPY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG4A | Patent for invention issued | ||
KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
MM4A | Patent for invention definitely lapsed due to non-payment of fees |